Trial intelligence / Profile preview

Topiramate for obesity

NCT00236613Phase 2Completed

Sponsor
Johnson & Johnson
Start
Sep 2000
Modality
Small Molecules
01

Overview

Phase 2, randomised, double-blind trial of topiramate in obesity (5 arms), sponsored by Johnson & Johnson. Primary endpoint: The percent change in body weight from baseline to Week 24. Started Sep 2000; status: completed.

02

Drugs

topiramate
03

Conditions

obesity

Beyond the preview

Go deeper on NCT00236613.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00236613.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call